FORM PTO-1449

1 3 2005 8

U.S. DEPARTMENT OF **COMMERCE PATENT** AND TRADEMARK

**OFFICE** 

List of Information Cited by Applicant

Page 1 of 2

ATTY, DOCKET NO. 00026.04CON

SERIAL NO. 10/734,902

APPLICANT

Rabinowitz, et al.

FILING DATE

**GROUP** 

December 12, 2003

1616

TRADEM			U.S. PAT	TENT DOCUMENTS			
EXAM. NITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DAT
181	1.	4,484,576	11/27/84	Albarda			
1	2.	4,566,451	01/28/86	Badewien		<u> </u>	
	3.	4,734,560	03/29/88	Bowen			
	4.	4,853,517	08/01/89	Bowen et al.			
	5.	4,303,083	12/01/81	Burruss, Jr.			
<b>—</b>	6.	5,099,861	03/31/92	Clearman et al.			
	7.	4,906,417	03/06/90	Gentry			
	8.	4,735,217	04/05/88	Gerth et al.	*		
	9.	5,840,246	11/24/98	Hammons et al.			
	10.	5,743,251	04/28/98	Howell et al.			
	11.	6,090,212	07/18/00	Mahawili			
	12.	5,146,915	09/15/92	Montgomery			
	13.	5,918,595	07/06/99	Olsson et al.		<u> </u>	
	14.	4,917,119	04/17/90	Potter et al.			<u> </u>
$\neg$	15.	4,941,483	07/17/90	Ridings et al.			
	16.	3,982,095	09/21/76	Robinson			
1	17.	5,605,146	02/25/97	Sarela			
$\gamma\gamma$	18.	5,456,247	10/10/95	Shilling et al.			

	•		FOREIGN PATE	NT DOCUMENTS			
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS
111	19.	WO 94/09842	05/11/94	PCT			<u> </u>
						<u> </u>	

	<del></del>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
M	20.	Office Action mailed 12/04/03 for US App. No. 10/057,198 filed 10/26/01 "Method And Device For Delivering A Physiologically Active Compound"
	21.	Office Action mailed 01/12/05 for US App. No. 10/057,197 filed 10/26/01, "Aerosol Generating Device And Method"
	22.	Office Action mailed 06/03/04 for US App. No. 10/057,197 filed 10/26/01, "Aerosol Generating Device And Method"
	23.	Office Action mailed 12/15/03 for US App. No. 10/057,197 filed 10/26/01, "Aerosol Generating Device And Method"
m	24.	Office Action mailed 02/27/04 for US App. No. 10/146,080 filed 05/13/02, "Aerosol Forming Device For Use In Inhalation Therapy"
EXAMINI	ER	DATE CONSIDERED 8/15/05
*EXAMIN	ER: Initia	I if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK

List of Information Cited by Applicant

Page 2 of 2

OFFICE

ATTY. DOCKET NO. 00026.04CON

SERIAL NO. 10/734,902

APPLICANT

Rabinowitz, et al.

FILING DATE

GROUP

December 12, 2003

1616

3,949,743   04/13/76   Shanbrom   14.   5,649,554   07/22/97   Sprinkel et al.   17.   5,592,934   01/14/97   Thwaites   18.   19.   5,894,841   04/20/99   Voges   19.   5,894,841   04/20/99   Voges   19.   5,874,481   02/23/99   Weers et al.   19.   2003/0032638   02/13/03   Kim et al.   19.   2003/0032638   02/13/03   Kim et al.   10/302,614   11/21/02   Lu   10/302,614   11/21/02   Lu   10/302,614   11/21/02   Lu   10/302,227   12/17/02   Novack et al.   10/32,227   12/17/02   Novack et al.   10/32,227   12/17/02   Novack et al.   10/850,895   05/20/03   Cross et al.   10/851,429   05/20/04   Hale et al.   10/851,432   05/20/04   Hale et al.   10/851,018   05/20/04   Hale et al.   10/917,735   08/12/04   Hale et al.   10/917,735   08/12/04   Hale et al.   10/917,730   08/12/04	EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
17.   5,592,934   01/14/97   Thwaites   128.   6,632,047   10/14/03   Vinegar et al.   129.   5,894,841   04/20/99   Voges   130.   5,366,770   11/22/94   Wang   131.   5,874,481   02/23/99   Weers et al.   132.   2003/0032638   02/13/03   Kim et al.   10/057,198   10/26/01   Lloyd et al.   10/302,614   11/21/02   Lu   135.   10/146,088   05/13/02   Hale et al.   10/280,315   10/25/02   Shen   10/322,227   12/17/02   Novack et al.   10/322,227   12/17/02   Novack et al.   10/442,385   05/20/03   Cross et al.   10/850,895   05/20/04   Hale et al.   10/851,429   05/20/04   Hale et al.   10/851,432   05/20/04   Hale et al.   10/851,018   05/20/04   Hale et al.   10/917,735   08/12/04   Hale et al.   10/917,735   08/12/04   Hale et al.   10/917,730   08/12/04   Hale et al.   10/917,7	M	25.	3,949,743	04/13/76	Shanbrom	1		
28. 6,632,047 10/14/03 Vinegar et al.  29. 5,894,841 04/20/99 Voges  30. 5,366,770 11/22/94 Wang  31. 5,874,481 02/23/99 Weers et al.  32. 2003/0032638 02/13/03 Kim et al.  33. 10/057,198 10/26/01 Lloyd et al.  34. 10/302,614 11/21/02 Lu  35. 10/146,088 05/13/02 Hale et al.  36. 10/280,315 10/25/02 Shen  37. 10/322,227 12/17/02 Novack et al.  38. 10/442,385 05/20/03 Cross et al.  39. 10/719,540 11/20/03 Hale et al.  40. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.	)	26.	5,649,554	07/22/97	Sprinkel et al.			
29.   5,894,841   04/20/99   Voges		27.	5,592,934	01/14/97	Thwaites			
30. 5,366,770 11/22/94 Wang 31. 5,874,481 02/23/99 Weers et al. 32. 2003/0032638 02/13/03 Kim et al. 33. 10/057,198 10/26/01 Lloyd et al. 34. 10/302,614 11/21/02 Lu 35. 10/146,088 05/13/02 Hale et al. 36. 10/280,315 10/25/02 Shen 37. 10/322,227 12/17/02 Novack et al. 38. 10/442,385 05/20/03 Cross et al. 39. 10/719,540 11/20/03 Hale et al. 40. 10/850,895 05/20/04 Damani et al. 41. 10/851,429 05/20/04 Hale et al. 42. 10/851,883 05/20/04 Hale et al. 43. 10/851,432 05/20/04 Hale et al. 44. 10/861,554 06/03/04 Cross et al. 45. 10/851,018 05/20/04 Hale et al. 46. 10/917,735 08/12/04 Hale et al. 47. 10/917,720 08/12/04 Hale et al.		28.	6,632,047	10/14/03	Vinegar et al.			
31. 5,874,481 02/23/99 Weers et al.  32. 2003/0032638 02/13/03 Kim et al.  33. 10/057,198 10/26/01 Lloyd et al.  34. 10/302,614 11/21/02 Lu  35. 10/146,088 05/13/02 Hale et al.  36. 10/280,315 10/25/02 Shen  37. 10/322,227 12/17/02 Novack et al.  38. 10/442,385 05/20/03 Cross et al.  39. 10/719,540 11/20/03 Hale et al.  40. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.  47. 10/917,720 08/12/04 Hale et al.		29.	5,894,841	04/20/99	Voges			
32   2003/0032638   02/13/03   Kim et al.		30.	5,366,770	11/22/94	Wang			
33. 10/057,198 10/26/01 Lloyd et al.  34. 10/302,614 11/21/02 Lu  35. 10/146,088 05/13/02 Hale et al.  36. 10/280,315 10/25/02 Shen  37. 10/322,227 12/17/02 Novack et al.  38. 10/442,385 05/20/03 Cross et al.  39. 10/719,540 11/20/03 Hale et al.  40. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.		31.	5,874,481	02/23/99	Weers et al.			
34. 10/302,614 11/21/02 Lu  35. 10/146,088 05/13/02 Hale et al.  36. 10/280,315 10/25/02 Shen  37. 10/322,227 12/17/02 Novack et al.  38. 10/442,385 05/20/03 Cross et al.  39. 10/719,540 11/20/03 Hale et al.  41. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.		32.	2003/0032638	02/13/03	Kim et al.			_
35.   10/146,088   05/13/02   Hale et al.		33.	10/057,198	10/26/01	Lloyd et al.			
36. 10/280,315 10/25/02 Shen  37. 10/322,227 12/17/02 Novack et al.  38. 10/442,385 05/20/03 Cross et al.  39. 10/719,540 11/20/03 Hale et al.  40. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.  47. 10/917,720 08/12/04 Hale et al.		34.	10/302,614	11/21/02	Lu			
36.       10/280,315       10/25/02       Shen         37.       10/322,227       12/17/02       Novack et al.         38.       10/442,385       05/20/03       Cross et al.         39.       10/719,540       11/20/03       Hale et al.         44.       10/850,895       05/20/04       Damani et al.         41.       10/851,429       05/20/04       Hale et al.         42.       10/851,883       05/20/04       Hale et al.         43.       10/851,432       05/20/04       Hale et al.         44.       10/861,554       06/03/04       Cross et al.         45.       10/851,018       05/20/04       Hale et al.         46.       10/917,735       08/12/04       Hale et al.         47.       10/917,720       08/12/04       Hale et al.		35.	10/146,088	05/13/02	Hale et al.			
38.       10/442,385       05/20/03       Cross et al.         39.       10/719,540       11/20/03       Hale et al.         40.       10/850,895       05/20/04       Damani et al.         41.       10/851,429       05/20/04       Hale et al.         42.       10/851,883       05/20/04       Hale et al.         43.       10/851,432       05/20/04       Hale et al.         44.       10/861,554       06/03/04       Cross et al.         45.       10/851,018       05/20/04       Hale et al.         46.       10/917,735       08/12/04       Hale et al.         47.       10/917,720       08/12/04       Hale et al.		36.	<del></del>	10/25/02	Shen			
39. 10/719,540 11/20/03 Hale et al.  41. 10/850,895 05/20/04 Damani et al.  41. 10/851,429 05/20/04 Hale et al.  42. 10/851,883 05/20/04 Hale et al.  43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.		37.	10/322,227	12/17/02	Novack et al.			
44.       10/850,895       05/20/04       Damani et al.         41.       10/851,429       05/20/04       Hale et al.         42.       10/851,883       05/20/04       Hale et al.         43.       10/851,432       05/20/04       Hale et al.         44.       10/861,554       06/03/04       Cross et al.         45.       10/851,018       05/20/04       Hale et al.         46.       10/917,735       08/12/04       Hale et al.         47.       10/917,720       08/12/04       Hale et al.		38.	10/442,385	05/20/03	Cross et al.			
41.       10/851,429       05/20/04       Hale et al.         42.       10/851,883       05/20/04       Hale et al.         43.       10/851,432       05/20/04       Hale et al.         44.       10/861,554       06/03/04       Cross et al.         45.       10/851,018       05/20/04       Hale et al.         46.       10/917,735       08/12/04       Hale et al.         47.       10/917,720       08/12/04       Hale et al.		39.	10/719,540	11/20/03	Hale et al.			
42.       10/851,883       05/20/04       Hale et al.         43.       10/851,432       05/20/04       Hale et al.         44.       10/861,554       06/03/04       Cross et al.         45.       10/851,018       05/20/04       Hale et al.         46.       10/917,735       08/12/04       Hale et al.         47.       10/917,720       08/12/04       Hale et al.		44,	10/850,895	05/20/04	Damani et al.			
43. 10/851,432 05/20/04 Hale et al.  44. 10/861,554 06/03/04 Cross et al.  45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.  47. 10/917,720 08/12/04 Hale et al.		41.	10/851,429	05/20/04	Hale et al.			
44.     10/861,554     06/03/04     Cross et al.       45.     10/851,018     05/20/04     Hale et al.       46.     10/917,735     08/12/04     Hale et al.       47.     10/917,720     08/12/04     Hale et al.		42.	<del></del>	05/20/04	Hale et al.			
45. 10/851,018 05/20/04 Hale et al.  46. 10/917,735 08/12/04 Hale et al.  47. 10/917,720 08/12/04 Hale et al.		43.	10/851,432	05/20/04	Hale et al.			
46. 10/917,735 08/12/04 Hale et al. 47. 10/917,720 08/12/04 Hale et al.		44,	10/861,554	06/03/04	Cross et al.			
47. 10/917,720 08/12/04 Hale et al.		45.	10/851,018	05/20/04	Hale et al.			
		46.	10/917,735	08/12/04	Hale et al.			
M 48. 10/912,417 08/04/04 Bennett et al.	+	47.	10/917,720	08/12/04	Hale et al.			
	M	48,	10/912,417	08/04/04	Bennett et al.		1	

	OTHER DOCUMENTS (Including Author	or, Title, Date, Pertinent Pages, Etc.)
	. 22.4	
EXAMINER	-HHZ	DATE CONSIDERED 8/15/05
	if reference considered, whether or not citation is in considered. Include copy of this form with next con	a conformance with MPEP 609; Draw line through citation if not in



FORM PTO-1449 U.S. DEPARTMENT OF AND TRADEMARK

COMMERCE PATENT OFFICE

List of Information Cited by Applicant Page 1 of 1

ATTY. DOCKET NO.	SERIAL NO.	
00026.04CON	10/734,902	
APPLICANT		
Rabinowitz, et al.		
FILING DATE	GROUP	
December 12, 2003	1616	

			U.S. PATEN	r documents			
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
M	1.	3,219,533	11/23/1965	Mullins	1		
1	Z.	4,141,369	02/27/1979	Burruss			
	3.	4,474,191	10/02/1984	Steiner			
	4.	4,708,151	11/24/1987	Shelar.			
	5.	4,819,665	04/11/1989	Roberts et al.			
	6.	4,848,374	07/18/1989	Chard et al.		7 7	
	7.	4,924,883	05/15/1990	Perfetti et al.			
	8.	4,963,289	10/16/1990	Ortiz et al.			
	9.	5,042,509	08/27/1991	Banerjee et al.			
	10.	5,060,671	10/29/1991	Counts et al.			
	11.	5,135,009	08/04/1992	Muller et al.			
	12.	5,144,962	09/08/1992	Counts et al.			
	13.	5,224,498	07/06/1993	Deevi et al.			
	14.	5,345,951	09/13/1994	Serrano et al.			
	15.	5,511,726	04/30/1996	Greenspan et al.			
	16.	5,564,442	10/15/1996	MacDonald et al.			
	17.	5,666,977	09/16/1997	Higgins et al.			
1	18.	5,819,756	10/13/1998	Mielordt			
	19.	5,855,913	01/05/1999	Hanes et al.			
	20.	6,095,134	08/01/2000	Sievers et al.			
	21. ~	6,131,570	10/17/2000	Schuster et al.			
	22.	6,136,295	10/24/2000	Edwards et al.			
	23.	6,155,268	12/05/2000	Takeuchi			
	24.	6,158,431	12/12/2000	Poole			
	25.	6,234,167	05/22/2001	Cox et al.			
	26.	2002/0117175	08/29/2002	Kottayil et al.			
1	27.	6,701,922	03/09/2004	Hindle et al.			
- /Y]	28.	6,772,756	08/10/2004	Shayan			

			FOREIGN PATEN	T DOCUMENTS			
EXAM. INITIĄL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS
MI	29.	GB 502 761	03/24/1939	Great Britain			
70	30.	WO 97/36574	10/09/1997	WIPO			
7N	31.	WO 03/037412	05/08/2003	WIPO			
XAMINER	. ,	Miles	-	DAT	E CONSIDE	RED 8/	15/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.